MedTrace Logo

CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer

NCT00434031 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-07-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the rate of pathologic complete response when giving docetaxel and trastuzumab followed by caelyx (liposomal doxorubicin), cyclophosphamide and trastuzumab before surgery in treating women with operable or locally advanced HER-2 positive breast cancer.

Conditions

Interventions

DRUG

docetaxel

DRUG

cyclophosphamide

DRUG

trastuzumab

DRUG

liposomal doxorubicin

Sponsors & Collaborators

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • Andrea De Matteis, M.D. · NCI Naples, Division of Medical Oncology C

  • Giuseppe D'Aiuto, M.D. · NCI Naples, Division of Surgical Oncology A

  • Francesco Perrone, M.D., Ph.D. · NCI Naples, Clinical Trials Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00434031 on ClinicalTrials.gov